Eli Lilly, Q2 2026

Page one — What they said

Extraction

• The GLP-1 franchise carried the print. Mounjaro grew 91% to $9.9B, split $4.8B U.S. and $5.2B international. Zepbound delivered $4.9B in the U.S. (+44%), with management explicit that prescription demand more than offset a decline in net price.
• First quarter with the oral in the mix. Foundayo (orforglipron), approved in April, contributed its first sales. The obesity franchise now has three commercial legs rather than two.
• International grew 80%, on Lilly's terms. Ex-U.S. revenue of $8.6B reflected +113% volume against a 36% price decline, driven largely by Mounjaro's addition to China's national reimbursement formulary — access breadth purchased with price.
• Guidance raised on the top line, capped on the bottom. FY26 revenue lifted to $85–87B; EPS guidance absorbs $3.03 of acquired IPR&D charges from in-quarter deal activity, alongside a further $4.5B committed to Indiana manufacturing.

Delta versus prior quarter

• The price/volume gap widened materially. The 60/(13) split is the sharpest divergence of the current cycle. Net price erosion is accelerating even as guidance rises, and management framed it as deliberate strategy rather than competitive slippage.
• BD posture moved from stated intent to committed capital. IPR&D charges of $3.03 per share against $0.14 a year ago mark a step-change in deal cadence.
• Medicare entered the obesity P&L. Part D coverage of obesity drugs went live in early July at roughly a $50 member copay. This is the first call where second-half guidance embeds a federally reimbursed obesity population.

Point of view

Competitors should stop reading this as an earnings beat and start reading it as a pricing doctrine. Lilly has demonstrated, across two geographies and three assets, that it will trade double-digit net price for category-defining volume — while gross margin still expands 130 basis points. That combination of manufacturing scale, price flexibility, and margin headroom is the moat. Any competitor carrying stable GLP-1 net pricing into 2027 contracting assumptions is planning against an opponent that no longer exists.

Page two — What it means

Market access implications

• Expect a harder Lilly posture in 2027 GLP-1 bid cycles. A franchise compounding at this rate, with demonstrated willingness to move on net price, gives Lilly credible walk-away power with PBMs. The leverage question inverts: excluding the category leader now carries member-disruption risk that payers will struggle to price.
• Part D obesity coverage changes the rebate math in the second half. A federally reimbursed obesity population at a $50 copay pulls a new, price-regulated volume pool into the mix. Watch how plans manage utilization — prior authorization design, step-through from older agents — because that is where the real access friction will surface, not on the formulary line itself.
• Foundayo is the access wildcard. An oral entering a franchise with two established injectables invites tiered portfolio contracting: bundling breadth in exchange for position. Competitors without an oral will be negotiating against a portfolio rather than a product.
• The price war is announced, not implied. Novo has committed to January 1, 2027 WAC reductions to $675 across the semaglutide portfolio — roughly 50% on Wegovy and 35% on Ozempic. List-price compression of that magnitude resets gross-to-net mechanics for the entire category. Rebate models built on 2026 WAC are already stale.
• China's NRDL is the template, not a one-off. A 36% international price decline for 113% volume is the same doctrine applied abroad, with eventual read-through to international reference pricing.

Business development implications

• Lilly is an aggressive, active buyer — and assets are priced accordingly. $3.03 per share of in-quarter IPR&D charges is a statement of intent. Expect Lilly in any competitive process for metabolic, obesity-adjacent, and next-generation incretin assets, and expect it to pay.
• Manufacturing capacity is a BD signal, not merely capex. The incremental $4.5B Indiana commitment indicates Lilly is building for assets it does not yet own.
• The bar for competing obesity assets has risen. Diligence must now model launch into a market where the leader will defend with price. Base-case net pricing assumptions from 2024–25 vintage models should be rerun before they inform a bid.
• Adjacent white space is where value migrates. With the core GLP-1 fight becoming a scale-and-price war, differentiated mechanisms — muscle preservation, oral combinations, cardiometabolic outcomes — are the rational hunting ground.

What we're watching next

• January 1, 2027 national formulary templates. First full cycle to reflect Part D obesity coverage and the Foundayo oral. Any change in GLP-1 tiering or utilization management confirms or kills the leverage thesis above.
• Second-half Part D obesity utilization. The pace of senior uptake at the $50 copay determines whether 2027 bids treat obesity as a managed category or an open one.
• Competitor language on the Q3 tape. Watch for net-price commentary from Novo and pipeline-stage entrants.
• Where the IPR&D dollars went. The 10-Q detail on in-quarter transactions maps Lilly's next access battleground before it becomes one.

Sources: company reports and Q2 2026 earnings materials. Unsourced commentary is the sole opinion of the author. Not investment advice. See full disclosures.